Elevance Health (ELV) Q2 2026 Earnings Call Transcript
Elevance Health (ELV) reported Q2 2026 adjusted diluted EPS of $7.45, exceeding internal projections, and raised full-year adjusted EPS guidance to at least $27. Operating revenue was $49.8B (+0.8% YoY) with medical membership of 44.9M. Management expects Medicaid margin trough around -1.75% in 2026, Medicare Advantage at least 2%, and full-year operating cash flow of at least $6B.
How this was made
The 30-second read
Why it matters
Key new trading inputs are the raised full-year adjusted EPS guidance, the 2027 growth target framework, and management’s quantified expectations for Medicaid margin trough and planned Medicaid market exits. These affect valuation via earnings trajectory and risk perception around medical cost trends and reimbursement timing.
Market read
Traders can update ELV earnings expectations using the raised EPS guidance and assess execution risk from Medicaid margin trough and planned market exits.
What to watch
Medicaid operating margin is guided to a trough in 2026 with elevated utilization and timing of rate adjustments, and CMS settlement remittance is an initial payment that may not fully represent ongoing net impact.
Background
The article is a transcript of Elevance Health’s Q2 2026 earnings call, covering segment performance, guidance, and Medicaid/Medicare Advantage execution.
Ticker impact
Elevance raised full-year adjusted EPS guidance to at least $27 and outlined 2026 Medicaid margin trough plus 12 to 18 month market exits.
Bullish bias for ELV on guidance raise, partially offset by Medicaid margin trough and ongoing cost/utilization pressure.
The transcript provides specific, time-bound financial guidance (Q2 adjusted EPS $7.45, full-year at least $27 raised) and concrete operational actions (DC Medicaid exit, additional exits in 12 to 18 months) that directly affect earnings expectations and execution risk.
Market effects
Managed care peers may see read-across on Medicare Advantage economics, Medicaid rate update sensitivity, and digital prior authorization automation benefits.
US Medicaid market exit actions (DC and additional markets) highlight state-by-state profitability dispersion.
Limited, as the drivers are primarily US payer reimbursement and CMS risk adjustment dynamics.
Counterpoint
The raised EPS outlook may rely on favorable benefit expense and rate alignment assumptions that could reverse if utilization or risk adjustment accruals deteriorate.
Key entities
- companyElevance Health
US managed care payer providing Q2 results, raised full-year adjusted EPS guidance, and Medicaid exit and margin-trough outlook.
- regulatorCMS
Medicare regulator referenced for a written confirmation closing a prior Medicare Advantage matter and a risk adjustment exposure remittance.
- business segmentCarelon
Elevance services brand referenced for behavioral health savings and CareBridge value-based home care cost reductions.
